Summary
Drug delivery by inhalation is routine for the treatment of local pulmonary conditions like asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Only recently, though, has the inhalation route been considered for administering drugs for systemic diseases. The pulmonary route is attractive for several reasons. It is non-invasive, it avoids first-pass metabolism, and it allows drug absorption from a large, highly vascularized surface area. However, consistent delivery to the deep lung requires drug particles within a very narrow size range. Several particle engineering approaches have been used to produce dry powders that will reach the alveolar space. Some of these methods, such as spray drying from solution, the formation of drug-containing liposomes, and the controlled crystallization of particles, are described here.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agu, R.U., et al. (2001) The lung as a route for systemic delivery of therapeutic proteins and peptides. Respiratory Research, 2: p. 198–209.
Laube, B. (2005) The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respiratory Care, 50: p. 1161–1176.
Clark, A.R., et al. (2006) The application of pulmonary inhalation technology to drug discovery. Annual Reports in Medicinal Chemistry, 41: p. 384–393.
Todo, H., et al. (2001) Effect of additives on insulin absorption from intratracheally administered dry powders in rats. International Journal of Pharmaceutics, 220: p. 101–110.
Stahl, K., et al. (2002) The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. International Journal of Pharmaceutics, 233: p. 227–237.
Bosquillon, C., et al. (2004) Aerosolization properties, surface composition and physical state of spray-dried protein powders. Journal of Controlled Release, 99: p. 357–367.
Codrons, V., et al. (2003) Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. Journal of Pharmaceutical Sciences, 92: p. 938–950.
Edwards, D.A., et al. (1997) Large porous particles for pulmonary drug delivery. Science, 279: p. 1868–1871.
Koushik, K., et al. (2004) Pulmonary delivery of deslorelin: large-porous PLGA particles and HPBCD complexes. Pharmaceutical Research, 21: p. 1119–1126.
Koushik, K. and U.B. Kompella (2004) Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharmaceutical Research, 21: p. 524–535.
Huang, Y.-Y. and C.-H. Wang (2006) Pulmonary delivery of insulin by liposomal carriers. Journal of Controlled Release, 113: p. 9–14.
Bustami, R., et al. (2000) Generation of micro particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharmaceutical Research, 17: p. 1360–1366.
Winters, M., et al. (1996) Precipitation of proteins in supercritical carbon dioxide. Journal of Pharmaceutical Sciences, 85: p. 586–594.
Mitchell, J. and M. Nagel (2004) KONA, 22: p. 32–65.
Lu, D. and A. Hickey (2005) Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech, 6: p. E641–E648.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kraft, K.S., Grant, M. (2009). Preparation of Macromolecule-Containing Dry Powders for Pulmonary Delivery. In: Belting, M. (eds) Macromolecular Drug Delivery. Methods in Molecular Biology, vol 480. Humana Press. https://doi.org/10.1007/978-1-59745-429-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-429-2_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-999-4
Online ISBN: 978-1-59745-429-2
eBook Packages: Springer Protocols